Financial Performance & Targets - Aptar reported FY 2024 sales of $3.6 billion[12], with Pharma contributing 46%, Beauty 34%, and Closures 20%[12] - Adjusted EBITDA for FY 2024 was $775 million[12], with Pharma accounting for 67%, Beauty 19%, and Closures 14%[12] - The company targets long-term core sales growth of 4-7% and an adjusted EBITDA margin of 21-23%[45] - Aptar Pharma targets core sales growth of 7-11% and an adjusted EBITDA margin of 32-36%[45] - Aptar Beauty targets core sales growth of 3-6% and an adjusted EBITDA margin of 15-17%[45] - Aptar Closures targets core sales growth of 4-7% and an adjusted EBITDA margin of 16-18%[45] Strategic Growth Drivers - Pharma's pipeline is expected to add 7-10% annual revenue, with approximately 90% of revenue being repeat business[43, 135] - The company returned $210 million to shareholders through dividends and share repurchases in the first half of 2025[37, 101] - Capital expenditure investments in Pharma represented 54% of the total, while Beauty and Closures accounted for 46% in 2024[96] Market Trends & Innovation - The obesity market is expected to grow at a 23-26% CAGR between 2024-2029[59] - 90% of consumers are more likely to buy brands with sustainable packaging[67]

Core Viewpoint - Aptar has announced an increase in its quarterly dividend by nearly 7%, indicating continued momentum and long-term strength in its financial performance [1] Financial Performance - The increase in the quarterly dividend reflects the company's robust financial health and commitment to returning value to shareholders [1] - The specific percentage increase in the dividend is nearly 7%, showcasing a positive trend in the company's profitability [1] Market Position - The decision to raise the dividend signals confidence in the company's ongoing operational performance and market position [1] - This move may attract more investors looking for stable dividend-paying stocks, potentially enhancing the company's market appeal [1]

Core Viewpoint - The FDA upheld the De Novo denial for CytoSorbents' DrugSorb-ATR device but found no safety issues, proposing a potential path forward for market authorization [2][3]. Regulatory Status - On August 14, 2025, the FDA issued a decision following an appeal regarding the De Novo application for DrugSorb-ATR, which was initially denied on April 25, 2025, due to the need for additional information [2][7]. - The FDA's appeal decision confirmed the device's safety but maintained the denial, indicating that further information is required to support the desired label indication [2][3]. - The FDA suggested a potential path forward for market authorization and noted that the company could appeal to a higher level within the FDA [2][7]. Company Insights - CytoSorbents Corporation specializes in blood purification technologies aimed at treating life-threatening conditions in intensive care and cardiac surgery [4][5]. - The company’s lead product, CytoSorb®, is already approved in the EU and has been used in nearly 300,000 devices globally [5]. - DrugSorb-ATR is designed to reduce perioperative bleeding in high-risk surgeries for patients on blood thinners, having received two FDA Breakthrough Device Designations [7][9]. Market Need - There is a significant need for solutions addressing perioperative bleeding in patients undergoing urgent coronary artery bypass graft (CABG) surgery, particularly those on ticagrelor [3][4]. - The technology aims to mitigate risks associated with blood thinners, which are increasingly common among patients, thereby addressing a critical issue faced by surgeons and patients alike [3][4].

Core Viewpoint - AptarGroup reported strong Q2 2025 earnings, with adjusted EPS of $1.66 exceeding estimates and GAAP revenue of $966 million surpassing forecasts, driven by margin improvement and sales growth in key segments despite macroeconomic uncertainties [1][2][5]. Financial Performance - Adjusted EPS for Q2 2025 was $1.66, up 18% from $1.41 in Q2 2024 [2] - GAAP revenue reached $966 million, a 6% increase from $910 million in the prior year [2] - Adjusted EBITDA was $218 million, reflecting a 13% year-over-year growth [2] - Adjusted EBITDA margin improved to 22.6%, up 1.4 percentage points from 21.2% in Q2 2024 [2] - Free cash flow was reported at $65.8 million, down 12.7% from $75.4 million in the previous year [2] Company Overview and Strategic Focus - AptarGroup specializes in packaging and dispensing systems for pharmaceuticals, beauty, food, and beverages, with products including nasal sprays and closures for food containers [3] - The company prioritizes innovation, regional manufacturing, and sustainability, focusing on R&D for advanced packaging solutions [4] Segment Performance - The Pharma segment accounted for 46% of sales, with a 7% revenue increase year-over-year and an adjusted EBITDA margin of 35.4% [5][8] - The Beauty segment saw a 4% revenue rise, with an adjusted EBITDA margin of 14.1% [6] - The Closures segment reported an 8% sales growth, achieving an adjusted EBITDA margin of 16.9% [7][8] Innovation and Product Development - New product launches included proprietary drug delivery systems and recyclable dispensers, with a focus on localizing supply chains to mitigate trade risks [10] - The Active Material Science division experienced an 11% increase in core sales, driven by demand for advanced drug delivery solutions [5] Capital Allocation and Shareholder Returns - The company returned $100 million to shareholders through buybacks and dividends, with year-to-date returns totaling $210 million [11] - Ongoing investments in plant and equipment highlight the company's commitment to expansion and operational improvement [11] Outlook - For Q3 2025, management projects adjusted EPS between $1.53 and $1.61, indicating flat performance compared to Q3 2024 [12] - Anticipated challenges include normalizing sales of naloxone and elevated cough and cold inventory in Europe [12] - The company continues to focus on sustainable packaging solutions to meet industry demands [13]

Company Overview - AptarGroup is a global supplier of innovative dispensing, sealing, and active packaging solutions for various markets including beauty, personal care, home care, prescription drugs, consumer health care, injectables, food, and beverages [12] - The company manufactures products such as dispensing pumps, closures, aerosol valves, and elastomeric primary packaging components, with facilities located in North America, Europe, Asia, and South America [12] Investment Analysis - AptarGroup currently holds a Zacks Rank of 3 (Hold) and has a VGM Score of B, indicating a solid position in the market [13] - The company is projected to experience year-over-year earnings growth of 4.3% for the current fiscal year, supported by upward revisions in earnings estimates from three analysts in the last 60 days [13] - The Zacks Consensus Estimate for AptarGroup's earnings has increased by $0.01 to $5.88 per share, with an average earnings surprise of +8.3% [13][14]

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED JUNE 30, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO COMMISSION FILE NUMBER 1-11846 AptarGroup, Inc. Delaware 36-3853103 (State of Incorporation) (I.R.S. Employer Identification No.) 265 EXCHANGE DRIVE, ...

Financial Data and Key Metrics Changes - The company reported adjusted earnings per share of $1.66, an increase of 18% compared to the prior year quarter [4] - Reported sales increased by 6%, with core sales growing by 3% year-over-year [15] - Adjusted EBITDA was $218 million, reflecting a 13% increase from the previous year [15] - The effective tax rate for the second quarter was 20%, down from 23.5% in the prior year [16] Business Segment Performance - The Pharma segment's core sales increased by 3%, with prescription sales up 8% and injectables up 9% [18] - Consumer Healthcare core sales decreased by 14% due to inventory management issues in Europe [18] - The Beauty segment saw core sales increase by 1%, driven by stronger tooling sales, while fragrance and skincare sales decreased by 4% [20] - The Closures segment's core sales increased by 7%, with food sales up 13% and beverage sales up 7% [22] Market Data and Key Metrics Changes - North America experienced solid growth in Consumer Healthcare, while Europe struggled with excess inventory from a weaker cold and flu season [6] - The company noted that the visibility into future European demand for cold and cough medications has not improved significantly [7] - The Prestige Beauty market faced headwinds from trade uncertainties, impacting demand recovery [10] Company Strategy and Industry Competition - The acquisition of Mod3 Pharma's clinical trial manufacturing capabilities is expected to enhance the company's position in the Pharma sector [8] - The company aims to expand its services into dermal, ophthalmic, injectable, and packaging solutions [9] - Cost management remains a priority across all segments, with ongoing initiatives to enhance earnings per share [34] Management's Comments on Operating Environment and Future Outlook - The management expressed confidence in the resilience and adaptability of the teams despite a complex macroeconomic backdrop [28] - The company anticipates challenges in the cough and cold markets in Europe and expects ongoing legal expenses related to intellectual property rights [30][32] - The management remains optimistic about the Pharma pipeline and the potential for systemic nasal drug delivery as a growth platform [31] Other Important Information - The company repurchased approximately 1 million shares for about $150 million in the first half of the year [14] - The company was recognized as one of Time Magazine's World Most Sustainable Companies for the second consecutive year [11] Q&A Session Summary Question: Can you provide more details on naloxone sales normalizing and its impact on core sales growth? - Management indicated that naloxone sales are expected to grow more mutedly in the coming quarters due to uncertainty and inventory issues [38] Question: What caused the significant inventory buildup in Consumer Healthcare? - Management explained that post-COVID demand spikes led to over-ordering, resulting in excess inventory that is now being worked off [52] Question: Can you elaborate on the legal expenditures related to intellectual property rights? - Management confirmed ongoing litigation to protect intellectual property, with expected legal costs of approximately $5 million to $6 million per quarter [82] Question: How is the acquisition in New Jersey expected to impact the business? - The acquisition is aimed at enhancing early-stage development capabilities, not for large-scale contract manufacturing [90] Question: What is the outlook for the Prestige Beauty market? - Management noted that while there are uncertainties, recent trade agreements may provide clarity for European clients, potentially boosting sales in the future [66]

Financial Data and Key Metrics Changes - The company reported adjusted earnings per share of $1.66, an increase of 18% compared to the prior year quarter [4][16] - Reported sales increased by 6%, with core sales growing by 3% year-over-year [15][22] - Adjusted EBITDA was $218 million, reflecting a 13% increase from the previous year [15] Business Line Data and Key Metrics Changes - Pharma segment core sales increased by 3%, with prescription sales up 8% and injectables up 9% [17][18] - Consumer Healthcare core sales decreased by 14% due to inventory management issues in Europe [17] - Beauty segment core sales increased by 1%, driven by stronger tooling sales, while fragrance and skincare saw a 4% decline [19] - Closures segment core sales increased by 7%, with food sales up 13% [20][21] Market Data and Key Metrics Changes - North America saw growth in Consumer Healthcare, while Europe struggled with excess inventory from a weaker cold and flu season [6][17] - The beverage market remained strong, with no significant issues reported despite competitor challenges [74] Company Strategy and Development Direction - The company announced the acquisition of Mod3 Pharma's clinical trial manufacturing capabilities, expanding its services in the Pharma sector [7] - Focus on innovation in drug delivery systems and expansion into new markets, including systemic nasal drug delivery [30] - Continued emphasis on cost management and operational efficiencies across all segments [22][32] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the resilience of the Pharma segment, despite challenges in the Consumer Healthcare division [27][30] - Anticipated continued growth in the Injectables market and a strong pipeline of new products [28][30] - Legal expenses related to intellectual property rights are expected to increase, impacting short-term profitability [25][84] Other Important Information - The company repurchased approximately 1 million shares for about $150 million in the first half of the year [14] - Recognized as one of Time Magazine's World Most Sustainable Companies for the second consecutive year [11] Q&A Session Summary Question: Can you provide more details on naloxone sales normalizing? - Management indicated that naloxone sales are expected to grow more slowly due to uncertainty in nontraditional distribution channels and recent federal guidance affecting funding [38][40] Question: What caused the extended downturn in Consumer Healthcare? - Management explained that post-COVID demand spikes led to inventory buildup, which is now being worked off, contributing to the downturn [54] Question: Can you elaborate on the legal expenditures related to intellectual property? - Management confirmed ongoing litigation to protect intellectual property rights, which is expected to continue for several quarters [61][84] Question: What is the outlook for the Beauty segment? - Management noted that while the Prestige Beauty market has faced challenges, recent tariff clarity may improve conditions moving forward [68][70]

Financial Performance - Q2 2025 reported sales grew by 6% to $966 million[7, 14], with core sales growth of 3%[7, 14] - Q2 2025 reported earnings per share (EPS) increased by 25% to $167[7, 16] - Q2 2025 adjusted EPS grew by 18% to $166[7, 19] - Q2 2025 adjusted EBITDA increased by 13% to $218 million[21] - Year-to-date 2025 reported sales increased by 2% to $1853 million[33], with core sales growth of 2%[33] - Year-to-date 2025 reported EPS increased by 10% to $283[35] - Year-to-date 2025 adjusted EBITDA increased by 8% to $402 million[41] Segment Performance - Aptar Pharma's Q2 2025 sales increased by 7% to $443 million[24], with a 130 basis point improvement in adjusted EBITDA margin to 354%[24] - Aptar Beauty's Q2 2025 sales increased by 4% to $335 million[27], with a 20 basis point improvement in adjusted EBITDA margin to 141%[27] - Aptar Closures' Q2 2025 sales increased by 8% to $189 million[30], with a 130 basis point improvement in adjusted EBITDA margin to 169%[30] Outlook - The company expects Q3 2025 adjusted EPS to be between $153 and $161[44]

Core Insights - AptarGroup (ATR) reported quarterly earnings of $1.66 per share, exceeding the Zacks Consensus Estimate of $1.58 per share, and up from $1.37 per share a year ago, representing an earnings surprise of +5.06% [1] - The company achieved revenues of $966.01 million for the quarter ended June 2025, surpassing the Zacks Consensus Estimate by 2.10% and increasing from $910.06 million year-over-year [2] - The stock has underperformed the market, losing about 0.2% since the beginning of the year compared to the S&P 500's gain of 8.2% [3] Earnings Outlook - The current consensus EPS estimate for the upcoming quarter is $1.62 on revenues of $948.99 million, and for the current fiscal year, it is $5.88 on revenues of $3.69 billion [7] - The estimate revisions trend for AptarGroup was mixed ahead of the earnings release, resulting in a Zacks Rank 3 (Hold) for the stock, indicating expected performance in line with the market [6] Industry Context - The Containers - Paper and Packaging industry, to which AptarGroup belongs, is currently ranked in the bottom 38% of over 250 Zacks industries, suggesting potential challenges for stock performance [8] - Empirical research indicates a strong correlation between near-term stock movements and trends in earnings estimate revisions, which can be tracked by investors [5]